John T Potts
Overview
Explore the profile of John T Potts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bilezikian J, Khan A, Clarke B, Mannstadt M, Potts J, Brandi M
J Bone Miner Res
. 2022 Oct;
37(11):2290-2292.
PMID: 36245277
No abstract available.
2.
Bilezikian J, Khan A, Silverberg S, Fuleihan G, Marcocci C, Minisola S, et al.
J Bone Miner Res
. 2022 Oct;
37(11):2293-2314.
PMID: 36245251
The last international guidelines on the evaluation and management of primary hyperparathyroidism (PHPT) were published in 2014. Research since that time has led to new insights into epidemiology, pathophysiology, diagnosis,...
3.
Bilezikian J, Silverberg S, Bandeira F, Cetani F, Chandran M, Cusano N, et al.
J Bone Miner Res
. 2022 Sep;
37(11):2391-2403.
PMID: 36054638
Since the last international guidelines were published in 2014 on the evaluation and management of primary hyperparathyroidism (PHPT), new information has become available with regard to evaluation, diagnosis, epidemiology, genetics,...
4.
Khan A, Bilezikian J, Brandi M, Clarke B, Gittoes N, Pasieka J, et al.
J Bone Miner Res
. 2022 Sep;
37(12):2568-2585.
PMID: 36054621
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international...
5.
Daley E, Yoon S, Reyes M, Bruce M, Brooks D, Bouxsein M, et al.
Endocrinology
. 2022 Apr;
163(7).
PMID: 35460406
Rodent models are commonly used to evaluate parathyroid hormone (PTH) and PTH-related protein (PTHrP) ligands and analogues for their pharmacologic activities and potential therapeutic utility toward diseases of bone and...
6.
Khan A, Brandi M, Potts J, Bilezikian J
J Clin Densitom
. 2013 Jan;
16(1):3.
PMID: 23294731
No abstract available.
7.
Khosla S, Bilezikian J, Dempster D, Lewiecki E, Miller P, Neer R, et al.
J Clin Endocrinol Metab
. 2012 Apr;
97(7):2272-82.
PMID: 22523337
Context: There has been considerable concern recently in the scientific and lay media regarding the benefits vs. the risks of bisphosphonates for the treatment of osteoporosis. Risks include possible associations...
8.
Ferrandon S, Feinstein T, Castro M, Wang B, Bouley R, Potts J, et al.
Nat Chem Biol
. 2009 Aug;
5(10):734-42.
PMID: 19701185
Cell signaling mediated by the G protein-coupled parathyroid hormone receptor type 1 (PTHR) is fundamental to bone and kidney physiology. It has been unclear how the two ligand systems--PTH, endocrine...
9.
Potts J, Gardella T
Ann N Y Acad Sci
. 2007 Dec;
1117:196-208.
PMID: 18056044
With the advent of advances in chemical and molecular biology, the structure of parathyroid hormone (PTH); the related protein, parathyroid-related protein (PTHrP); and their principal receptor (PTH/PTHrP receptor [PTHR1]) were...
10.
Potts J
J Endocrinol
. 2006 Jan;
187(3):311-25.
PMID: 16423810
Research on parathyroid hormone (PTH) has undergone four rather distinctive phases, beginning just before the turn of the 20th century. Early debates about the function of the parathyroids were resolved...